Biopharma | June 08, 2026
Biocon Academy graduates 156 students at 10th convocation
The graduating cohort comprised seven batches across five specialized programs
The graduating cohort comprised seven batches across five specialized programs
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
In his new role, Karthik will lead human capital strategy and HR operations across these regions
Former Global Head of IT & Digital Transformation at Biocon Biologics steps into enterprise-wide technology leadership role
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Move aligns global biologics identity under the Biocon Biologics brand
Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
